Multimedia

Alex Bacchetti, executive lead of the Center of Operational Transformation, AVIA, shares staffing ideas and technological solutions for health systems to improve recruiting and alleviate burnout now that the pandemic has exacerbated the labor...

Omar Sinno, MD, MBA, medical lead, rare disease, UCB, walks through the findings and implications of the phase 3 RAISE study which evaluated zilucoplan for the treatment of patients with myasthenia gravis.

Stephanie Ostling Mason, PharmD, CDCES, diabetes clinical pharmacist, Glytec, shares the challenges associated with insulin management in the hospital setting and offers advice to improve patient outcomes.

Joe Gagnon, CEO, 1upHealth, reviews how fast health care interoperability resources (FHIR) can aid organizations in improving data collection, care quality, and the consumer experience.

Scott Galbari, chief operating officer, Lyniate, shares challenges payers and providers have faced while trying to meet interoperability requirements and offers advice for organizations hoping to adopt new technologies to ease the process.

Shawn Kwatra, MD, FAAD, director, Johns Hopkins Itch Center, shares findings from a recent analysis of two phase 3 trials which investigated the efficacy and safety of a Janus kinase inhibitor for patients with moderate to severe atopic...

Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary, Mayo Clinic, offers insight into drug spending trends that emerged over the course of 2021 and predicts how spending will continue to change as the pandemic wanes and inflation...

Michael Ganio, PharmD, MS, senior director of pharmacy practice and quality, American Society of Health-System Pharmacists, discusses measures being taken to address the rise in monkeypox cases in the United States and reviews the efficacy of...

In the second part of this roundtable, Edmund Pezalla, MD, MPH; Adam Kittai, MD; Farrukh Awan, MD; and Jeffrey Dunn, PharmD, MBA, discuss cost and access challenges for treating patients with zanubrutinib.

In the first part of this roundtable, Edmund Pezalla, MD, MPH; Adam Kittai, MD; Farrukh Awan, MD; and Jeffrey Dunn, PharmD, MBA, discuss how second-generation BTK inhibitors are changing the treatment paradigm and payer considerations in...